 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- RSV Vaccine / Pfizer
Potential Public Health Impact of Respiratory Syncytial Virus (RSV) Vaccines for Prevention of Lower Respiratory Tract Disease (LRTD) Due to RSV Among Older Adults in Canada () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_972;
Moderna
- RSV Vaccine / Pfizer
Observational data, Retrospective data, Journal: Immediate post-discharge care among US adults hospitalized with respiratory syncytial virus infection. (Pubmed Central) - Oct 5, 2024
Immediate post-discharge care needs among adults hospitalized with RSV, especially in older adults, can be considerable and comparable to influenza and acute MI discharges. With recently approved RSV vaccines, efforts to increase vaccination in older adults are needed to prevent RSV and associated healthcare consequences.
- RSV Vaccine / Pfizer
Potential Public Health Impact of Respiratory Syncytial Virus (RSV) Vaccines for Prevention of RSV Among Older Adults in the United States (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2588;
- Abrysvo (PF-06928316) / Pfizer
Efficacy of a Bivalent RSVpreF Vaccine in Older Adults Across a Second RSV Season (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2587;
- Abrysvo (PF-06928316) / Pfizer
Public Health Impact of RSVpreF Vaccination on Older Adult Disease Outcomes (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2574;
- Comparison of Three RSV Vaccine Lower Respiratory Tract Disease Primary Endpoint Definitions for Adult Vaccine (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1035;
- Abrysvo (PF-06928316) / Pfizer
RSVpreF Vaccine Elicits a Robust and Durable Immune Response Among Adults Aged 60 Years and Older Across an Entire RSV Season (Marriott Marquis San Diego Marina, Grand Ballroom 11-13 (Lobby Level, North Tower)) - Mar 17, 2024 - Abstract #ATS2024ATS_8458;
Vaccination with bivalent RSVpreF elicits a strong immune response in adults 60 years of age and older, and the response remains durable throughout an entire RSV season and beginning of the subsequent season. Subgroup analyses support the previously observed consistent VE across different age and risk groups.
- RSV Vaccine / Pfizer, Abrysvo (PF-06928316) / Pfizer
Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Stabilized Prefusion F Subunit Vaccine (RSVpreF) Among Older Adults in Canada () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2270;
Subgroup analyses support the previously observed consistent VE across different age and risk groups. RSVpreF, Pfizer
- | RSV Vaccine / Pfizer
Journal: Estimated Respiratory Syncytial Virus-Related Hospitalizations and Deaths Among Children and Adults in Spain, 2016-2019. (Pubmed Central) - Feb 6, 2024
Like other respiratory viruses, RSV contributes to both respiratory and cardiovascular complications. Efficacious RSV vaccines could have a high public health impact in these age and risk groups.
- RSV Vaccine / Pfizer
The road to developing an RSV vaccine for older adults (Room 4) - Oct 20, 2023 - Abstract #WVCE2023WVCE_166;
- RSV Vaccine / Pfizer
Respiratory Syncytial Virus-Associated Health Care Utilization in the Pivotal Phase 3 Trial RSV Vaccine Efficacy Study In Older Adults Immunized Against RSV Disease (RENOIR) (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_3040;
- Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High Neutralizing Titers in Older Adults (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_3038;
- RSV Vaccine / Pfizer
Clinical Profile of Acute Respiratory Illness (ARI) Events in the Phase 3 Trial The RSV Vaccine Efficacy Study iN Older Adults Immunized against RSV Disease (RENOIR) (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_3036;
- | RSV Vaccine / Pfizer
Journal: Vaccine-Preventable Hospitalisations from Seasonal Respiratory Diseases: What Is Their True Value? (Pubmed Central) - May 27, 2023
Efficacious RSV vaccines could have a high public health impact in these age and risk groups. This paper estimates the number of hospitalisations that current vaccines against influenza, pneumococcal disease (PD), COVID-19, and a hypothetical Respiratory Syncytial Virus (RSV) vaccine, could prevent in the winter among older adults in England...However, the value of hospital beds freed up by vaccination is likely to be 1.1-2 times larger (
- ||||| RSV Vaccine / Pfizer
Clinical, Launch Europe, Launch US: U.S. drugmaker Pfizer is ready to launch its respiratory syncytial virus (#RSV) vaccine for both older adults and pregnant women in the United States and Europe later this year. https://t.co/JFMvPuOu5x (Twitter) - Mar 9, 2023
- ||||| RSV Vaccine / Pfizer
Clinical: RSV: Need vaccine for older adults, neonates. Pfizer released data their protein-based bivalent RSV vaccine 86% protective for older adults severe disease in summer; Moderna now provides data their mRNA RSV vaccine protects older adults by 84% from RSV https://t.co/aV7QmLMAve (Twitter) - Jan 17, 2023
- ||||| RSV Vaccine / Pfizer
Clinical, Review: A respiratory syncytial virus, or RSV, vaccine for older adults could be on the horizon after Pfizer announced Wednesday that the @US_FDA would review its experimental vaccine. The federal health agency will make a decision by May 2023. https://t.co/NCN1VOu0rD (Twitter) - Dec 7, 2022
- ||||| RSV Vaccine / Pfizer, RSV vaccine (GSK3844766A) / GSK, PF-06928316 / Pfizer
Clinical, P3 data: 15/ 🧬🗞️Right now, there are 2 protein subunit-based #RSV vaccines in Phase 3 trials for older adults: 🧪 RSVpreF Protein Subunit (Pfizer) 🧪 RSVPreF3-OA (GSK) #BonumCE #IDMedEd #IDTwitter #MedTwitter (Twitter) - Nov 4, 2022
- PF-06928316 / Pfizer
Efficacy And Safety Of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine In Older Adults (209 ABC) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2458;
- Rates of Medically-Attended RSV among US Adults: A Systematic Review and Meta-Analysis (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2212;
- || RSV Vaccine / Pfizer
Retrospective data, Review, Journal: Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis. (Pubmed Central) - Jul 27, 2022
The true burden of RSV has been underestimated and is significant among older adults and individuals with chronic medical conditions. A highly effective adult RSV vaccine would have substantial public health impact.
- | RSV Vaccine / Pfizer, PF-06928316 / Pfizer
Journal: Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study. (Pubmed Central) - Jun 29, 2022
P2a
These findings provide support for further evaluation of RSVpreF vaccine in a phase 3 efficacy study. (Funded by Pfizer; EudraCT number, 2020-003887-21; ClinicalTrials.gov number, NCT04785612.).
- |||||| RSV Vaccine / Pfizer
Trial termination: A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults (clinicaltrials.gov) - Mar 25, 2021
P2, N=304, Terminated, Sponsor: Pfizer
(Funded by Pfizer; EudraCT number, 2020-003887-21; ClinicalTrials.gov number, NCT04785612.). Completed --> Terminated; Study halted prematurely by sponsor and will not resume, participants are no longer being examined or receiving intervention.
- |||| RSV Vaccine / Pfizer
Trial completion: A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults (clinicaltrials.gov) - Mar 4, 2021
P2, N=1235, Completed, Sponsor: Pfizer
Completed --> Terminated; Study halted prematurely by sponsor and will not resume, participants are no longer being examined or receiving intervention. Active, not recruiting --> Completed
- |||| RSV Vaccine / Pfizer
Trial completion: A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults (clinicaltrials.gov) - Sep 13, 2020
P2, N=317, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || RSV Vaccine / Pfizer
Trial completion date: A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults (clinicaltrials.gov) - Aug 23, 2020
P2, N=317, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Trial completion date: Feb 2021 --> Sep 2020
- || RSV Vaccine / Pfizer
Trial completion date, Trial primary completion date: A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults (clinicaltrials.gov) - Aug 11, 2020
P2, N=317, Active, not recruiting, Sponsor: Pfizer
Trial completion date: Feb 2021 --> Sep 2020 Trial completion date: Jul 2021 --> Feb 2021 | Trial primary completion date: Jul 2021 --> Jun 2020
- ||| RSV Vaccine / Pfizer
Enrollment closed: A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults (clinicaltrials.gov) - Mar 11, 2020
P2, N=317, Active, not recruiting, Sponsor: Pfizer
Trial completion date: Jul 2021 --> Feb 2021 | Trial primary completion date: Jul 2021 --> Jun 2020 Recruiting --> Active, not recruiting
- || RSV Vaccine / Pfizer
Trial completion date, Trial primary completion date: A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults (clinicaltrials.gov) - Mar 9, 2020
P2, N=312, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Trial completion date: Apr 2021 --> Jul 2021 | Trial primary completion date: Apr 2021 --> Jul 2021
- |||| RSV Vaccine / Pfizer
Trial completion: A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS (clinicaltrials.gov) - Feb 20, 2020
P2b, N=712, Completed, Sponsor: Pfizer
Trial completion date: Apr 2021 --> Jul 2021 | Trial primary completion date: Apr 2021 --> Jul 2021 Recruiting --> Completed
- |||| RSV Vaccine / Pfizer
Enrollment open: A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS (clinicaltrials.gov) - Nov 27, 2019
P2b, N=710, Recruiting, Sponsor: Pfizer
Recruiting --> Completed Not yet recruiting --> Recruiting
- | RSV Vaccine / Pfizer
New P2b trial: A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS (clinicaltrials.gov) - Aug 28, 2019
P2b, N=680, Not yet recruiting, Sponsor: Pfizer
- | RSV Vaccine / Pfizer
Trial completion date, Trial primary completion date: A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults (clinicaltrials.gov) - Aug 21, 2019
P2, N=312, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Trial completion date: Jul 2020 --> Mar 2021 | Trial primary completion date: Jul 2020 --> Mar 2021
- | RSV Vaccine / Pfizer
Enrollment closed, Trial completion date: A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults (clinicaltrials.gov) - Aug 1, 2019
P2, N=1235, Active, not recruiting, Sponsor: Pfizer
Trial completion date: Jul 2020 --> Mar 2021 | Trial primary completion date: Jul 2020 --> Mar 2021 Recruiting --> Active, not recruiting | Trial completion date: Oct 2019 --> Nov 2020
- |||| RSV Vaccine / Pfizer
Enrollment open: A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults (clinicaltrials.gov) - May 17, 2019
P2, N=312, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting | Trial completion date: Oct 2019 --> Nov 2020 Suspended --> Recruiting
- | RSV Vaccine / Pfizer
Enrollment change: A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults (clinicaltrials.gov) - Feb 7, 2019
P2, N=312, Suspended, Sponsor: Pfizer
Suspended --> Recruiting N=474 --> 312
- RSV Vaccine / Pfizer
Trial completion date, Trial primary completion date: A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults (clinicaltrials.gov) - Oct 10, 2018
P2, N=474, Suspended, Sponsor: Pfizer
N=474 --> 312 Trial completion date: Nov 2019 --> Jun 2020 | Trial primary completion date: Nov 2019 --> Jun 2020
- |||||| RSV Vaccine / Pfizer
Trial suspension: A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults (clinicaltrials.gov) - Sep 13, 2018
P2, N=474, Suspended, Sponsor: Pfizer
Trial completion date: Nov 2019 --> Jun 2020 | Trial primary completion date: Nov 2019 --> Jun 2020 Recruiting --> Suspended
- ||||| RSV Vaccine / Pfizer
New P2 trial: A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults (clinicaltrials.gov) - Jun 27, 2018
P2, N=474, Recruiting, Sponsor: Pfizer
- ||||| RSV Vaccine / Pfizer
New P2 trial: A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults (clinicaltrials.gov) - May 18, 2018
P2, N=1182, Recruiting, Sponsor: Pfizer